Notably, evidence suggests that the other disease modifying therapies glatiramer acetate and natalizumab do not appear to worsen migraine, and indeed some patients may want to take this into consideration as switching from interferon beta may help reduce both frequency and severity of migraine [26]–[27]. This evidence concerns the gene IFNB1 and migraine disorder.